Abstract: The disclosed systems and methods include displaying disease trigger icons within a disease trigger map in a GUI, where the disease trigger map corresponds to a particular disease symptom, and where the position and size of a particular trigger icon within the trigger map based one or more of (i) the degree or strength of a statistical association between the trigger icon's corresponding disease trigger and the disease symptom, and (ii) a cumulative frequency and/or amount of exposure to the trigger icon's corresponding disease trigger. Some embodiments also include displaying a patient population disease trigger map one or more relationships between (i) one or more disease triggers and (ii) one or more patients of the patient population. Some embodiments may further include facilitating communication and/or disease trigger information sharing among patients.

Abstract: Example embodiments disclosed herein relate to methods and systems for determining whether particular actions affect or influence medical symptoms of patients. In one example, a plurality of datasets from a corresponding plurality of patients is received, where each patient has a corresponding disease. An individual dataset for an individual patient may include information about at least one disease symptom of the patient and at least one action of the patient. After the datasets are received from the patients, the datasets are stored in a database. Using the datasets stored in the database, a correlation between one or more actions and one or more disease symptoms may be determined based on a statistical analysis of the actions and symptoms stored in the database. The correlation between the one or more actions and the one or more disease symptoms may also be stored in the database.

Abstract: The disclosed systems and methods include providing a plurality of sounds at varying intensity levels, and receiving an input indicative of a perceived volume level of the plurality of sounds as perceived by a user. The disclosed systems and methods include determining, based on the received input, a plurality of user volume levels that indicate a hearing sensitivity of the user. The disclosed systems and methods include providing a background sound, and concurrently while providing the background sound, providing a stimulus sound. The disclosed systems and methods include receiving an indication that the user perceived the stimulus sound. The disclosed systems and methods include determining a change in the hearing sensitivity of the user based on receiving the indication that the user perceived the stimulus sound, and predicting an onset of a migraine attack of the user based on determining the change in the hearing sensitivity of the user.

Abstract: The disclosed systems and methods include displaying disease trigger icons within a disease trigger map in a GUI, where the disease trigger map corresponds to a particular disease symptom, and where the position and size of a particular trigger icon within the trigger map based one or more of (i) the degree or strength of a statistical association between the trigger icon's corresponding disease trigger and the disease symptom, and (ii) a cumulative frequency and/or amount of exposure to the trigger icon's corresponding disease trigger. Some embodiments also include displaying a patient population disease trigger map one or more relationships between (i) one or more disease triggers and (ii) one or more patients of the patient population. Some embodiments may further include facilitating communication and/or disease trigger information sharing among patients.

Abstract: The disclosed systems and methods include displaying disease trigger icons within a disease trigger map in a GUI, where the disease trigger map corresponds to a particular disease symptom, and where the position and size of a particular trigger icon within the trigger map based one or more of (i) the degree or strength of a statistical association between the trigger icon's corresponding disease trigger and the disease symptom, and (ii) a cumulative frequency and/or amount of exposure to the trigger icon's corresponding disease trigger. Some embodiments also include displaying a patient population disease trigger map one or more relationships between (i) one or more disease triggers and (ii) one or more patients of the patient population. Some embodiments may further include facilitating communication and/or disease trigger information sharing among patients.

Abstract: The disclosed systems and methods include receiving, individual tracking data corresponding to a patient, determining. Systems and methods further include, based on (i) the individual tracking data and (ii) aggregate tracking data received by the health management application from a population of patients, a list of no-association factors (NAFs) for the patient. Systems and methods further include determining that the patient has been exposed to a particular NAF a minimum threshold number of times without experiencing a particular disease symptom associated with the particular NAF. Systems and methods further include, providing patient feedback in response to determining that the patient has been exposed to the particular NAF the threshold number of times without experiencing the particular disease symptom, where providing the patient feedback includes providing an indication of the particular NAF.

Abstract: Embodiments disclosed herein include receiving disease symptom and disease factor inputs from a patient population comprising a plurality of patients, determining whether individual disease factors tend to cause individual patients in the patient population to experience individual disease symptoms or prevent individual patients in the patient population from experiencing individual disease symptoms, and causing a graphical user interlace to display a patient population trigger visualization for the disease symptoms, wherein the trigger visualization comprises a plurality of rows and one or more columns, wherein a first column corresponds to a first disease symptom for a first patient, and wherein a first row in the first column comprises an indication of an extent to which a first risk factor is a disease trigger or disease protector for the first disease symptom for the first patient.

Abstract: The disclosed systems and methods include displaying disease trigger icons within a disease trigger map in a GUI, where the disease trigger map corresponds to a particular disease symptom, and where the position and size of a particular trigger icon within the trigger map based one or more of (i) the degree or strength of a statistical association between the trigger icon's corresponding disease trigger and the disease symptom, and (ii) a cumulative frequency and/or amount of exposure to the trigger icon's corresponding disease trigger. Some embodiments also include displaying a patient population disease trigger map one or more relationships between (i) one or more disease triggers and (ii) one or more patients of the patient population. Some embodiments may further include facilitating communication and/or disease trigger information sharing among patients.

Abstract: Example embodiments disclosed herein relate to methods and systems for determining whether particular actions affect or influence medical symptoms of patients. In one example, a plurality of datasets from a corresponding plurality of patients is received, where each patient has a corresponding disease. An individual dataset for an individual patient may include information about at least one disease symptom of the patient and at least one action of the patient. After the datasets are received from the patients, the datasets are stored in a database. Using the datasets stored in the database, a correlation between one or more actions and one or more disease symptoms may be determined based on a statistical analysis of the actions and symptoms stored in the database. The correlation between the one or more actions and the one or more disease symptoms may also be stored in the database.

Abstract: One aspect of the present invention is a pharmaceutical combination comprising (a) an anti-inflammatory agent/anti-oxidant agent conjugate; and (b) an insulin secretogogue, an insulin sensitizer, an alpha-glucosidase inhibitor, a peptide analog, or a combination thereof. Another aspect of the invention relates to methods of treating metabolic disorders with such conjugates.

Abstract: This invention is directed to pharmaceutical combinations comprising an antioxidant agent, an anti-inflammatory agent, and optionally at least one other anti-diabetic agent useful for treating metabolic disorders. This invention also encompasses pharmaceutically acceptable compositions comprising an antioxidant agent, an anti-inflammatory agent, optionally at least one other anti-diabetic agent, and at least one pharmaceutically acceptable carrier.

Abstract: The present invention is directed to methods for treating metabolic disorders with compounds that are conjugates. The conjugates of the present invention are comprised of salicylic acid, triflusal, diflusinal, salsalate, IMD-0354, ibuprofen, diclofenac, licofelone, or HTB, and one or more antioxidants.

Abstract: The present invention is directed to methods for treating metabolic disorders with compounds that are conjugates. The conjugates of the present invention are comprised of salicylic acid, triflusal, diflusinal, salsalate, IMD-0354, ibuprofen, diclofenac, licofelone, or HTB, and one or more antioxidants.

Abstract: The present invention is directed to methods for treating metabolic disorders with compounds that are conjugates. The conjugates of the present invention are comprised of salicylic acid, triflusal, diflusinal, salsalate, IMD-0354, ibuprofen, diclofenac, licofelone, or HTB, and one or more antioxidants.

Abstract: The invention is directed to thiocarbonate compounds of Formula (I)-(III) and methods of treating atherosclerosis, neuropathy, nephropathy, retinopathy, inflammatory disorders, COPD, cardiovascular diseases, metabolic disorders, type I diabetes mellitus, type II diabetes mellitus, LADA, Wolfram Syndrome 1, Wolcott-Rallison syndrome, metabolic syndrome, dyslipidemia, hyperglycemia, or insulin resistance. The compounds of the invention are also useful for protecting pancreatic beta-cells and for reducing free fatty acids, triglycerides, advanced glycated end products, ROS, lipid peroxidation, tissue and plasma TNFalpha and IL6 levels, or for delaying or preventing cardiovascular complications associated with atherosclerosis.

Abstract: The invention is directed to thiocarbonate compounds of Formula (I)-(III) and methods of treating atherosclerosis, neuropathy, nephropathy, retinopathy, inflammatory disorders, COPD, cardiovascular diseases, metabolic disorders, type I diabetes mellitus, type II diabetes mellitus, LADA, Wolfram Syndrome 1, Wolcott-Rallison syndrome, metabolic syndrome, dyslipidemia, hyperglycemia, or insulin resistance. The compounds of the invention are also useful for protecting pancreatic beta-cells and for reducing free fatty acids, triglycerides, advanced glycated end products, ROS, lipid peroxidation, tissue and plasma TNFalpha and IL6 levels, or for delaying or preventing cardiovascular complications associated with atherosclerosis.

Abstract: The invention is directed to thiocarbonate compounds of Formula (I)-(III) and methods of treating atherosclerosis, neuropathy, nephropathy, retinopathy, inflammatory disorders, COPD, cardiovascular diseases, metabolic disorders, type I diabetes mellitus, type II diabetes mellitus, LADA, Wolfram Syndrome 1, Wolcott-Rallison syndrome, metabolic syndrome, dyslipidemia, hyperglycemia, or insulin resistance. The compounds of the invention are also useful for protecting pancreatic beta-cells and for reducing free fatty acids, triglycerides, advanced glycated end products, ROS, lipid peroxidation, tissue and plasma TNFalpha and IL6 levels, or for delaying or preventing cardiovascular complications associated with atherosclerosis.

Abstract: This invention is directed to pharmaceutical combinations comprising an antioxidant agent, an anti-inflammatory agent, and optionally at least one other anti-diabetic agent useful for treating metabolic disorders. This invention also encompasses pharmaceutically acceptable compositions comprising an antioxidant agent, an anti-inflammatory agent, optionally at least one other anti-diabetic agent, and at least one pharmaceutically acceptable carrier.

Abstract: The present invention is directed to methods for treating metabolic disorders with compounds that are conjugates. The conjugates of the present invention are comprised of salicylic acid, triflusal, diflusinal, salsalate, IMD-0354, ibuprofen, diclofenac, licofelone, or HTB, and one or more antioxidants.

Abstract: The present invention is directed to methods for treating metabolic disorders with compounds that are conjugates. The conjugates of the present invention are comprised of salicylic acid, triflusal, diflusinal, salsalate, IMD-0354, ibuprofen, diclofenac, licofelone, or HTB, and one or more antioxidants.